Cellectis Analyst Ratings
Cellectis Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/01/2023 | 112.39% | JMP Securities | $6 → $6 | Reiterates | Market Outperform → Market Outperform |
08/08/2023 | 289.38% | Oppenheimer | → $11 | Reiterates | Outperform → Outperform |
08/07/2023 | 112.39% | JMP Securities | → $6 | Reiterates | Market Outperform → Market Outperform |
04/05/2023 | 466.37% | Citigroup | $24 → $16 | Maintains | Buy |
03/13/2023 | 360.18% | Oppenheimer | $16 → $13 | Maintains | Outperform |
03/13/2023 | 112.39% | JMP Securities | → $6 | Reiterates | → Market Outperform |
01/19/2023 | 112.39% | JMP Securities | $11 → $6 | Maintains | Market Outperform |
05/24/2022 | -29.2% | Goldman Sachs | $3 → $2 | Maintains | Sell |
05/18/2022 | — | Baird | Upgrades | Neutral → Outperform | |
05/13/2022 | 147.79% | Barclays | $9 → $7 | Maintains | Overweight |
01/06/2022 | 466.37% | Wells Fargo | → $16 | Downgrades | Overweight → Equal-Weight |
11/30/2021 | 607.96% | JMP Securities | → $20 | Initiates Coverage On | → Market Outperform |
10/08/2021 | 253.98% | Baird | $39 → $10 | Downgrades | Outperform → Neutral |
04/28/2021 | — | Guggenheim | Downgrades | Buy → Neutral | |
03/16/2021 | 1280.53% | Baird | $23 → $39 | Upgrades | Neutral → Outperform |
10/15/2020 | — | Baird | Downgrades | Outperform → Neutral | |
08/19/2020 | 1032.74% | Citigroup | $15 → $32 | Upgrades | Neutral → Buy |
07/07/2020 | 643.36% | Baird | $28 → $21 | Maintains | Outperform |
03/06/2020 | 289.38% | Goldman Sachs | $15 → $11 | Downgrades | Neutral → Sell |
02/19/2020 | 1280.53% | BTIG | $37 → $39 | Maintains | Buy |
08/09/2019 | — | BTIG | Initiates Coverage On | → Buy | |
05/24/2019 | — | Citigroup | Assumes | → Neutral | |
03/14/2019 | — | William Blair | Initiates Coverage On | → Outperform | |
12/19/2018 | 784.96% | Goldman Sachs | → $25 | Initiates Coverage On | → Neutral |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
11/01/2023 | 112.39% | JMP 证券 | 6 美元 → 6 美元 | 重申 | 市场跑赢大盘 → 市场跑赢大盘 |
08/08/2023 | 289.38% | 奥本海默 | → 11 美元 | 重申 | 跑赢大盘 → 跑赢大盘 |
08/07/2023 | 112.39% | JMP 证券 | → 6 美元 | 重申 | 市场跑赢大盘 → 市场跑赢大盘 |
04/05/2023 | 466.37% | 花旗集团 | 24 美元 → 16 美元 | 维护 | 买 |
03/13/2023 | 360.18% | 奥本海默 | 16 美元 → 13 美元 | 维护 | 跑赢大盘 |
03/13/2023 | 112.39% | JMP 证券 | → 6 美元 | 重申 | → 市场跑赢大盘 |
01/19/2023 | 112.39% | JMP 证券 | 11 美元 → 6 美元 | 维护 | 市场表现跑赢大盘 |
2022 年 5 月 24 日 | -29.2% | 高盛 | 3 美元 → 2 美元 | 维护 | 卖出 |
05/18/2022 | — | 贝尔德 | 升级 | 中性 → 跑赢大盘 | |
05/13/2022 | 147.79% | 巴克莱 | 9 美元 → 7 美元 | 维护 | 超重 |
01/06/2022 | 466.37% | 富国银行 | → 16 美元 | 降级 | 超重 → 重量相等 |
2021 年 11 月 30 日 | 607.96% | JMP 证券 | → 20 美元 | 启动覆盖范围开启 | → 市场跑赢大盘 |
2021 年 8 月 10 日 | 253.98% | 贝尔德 | 39 美元 → 10 美元 | 降级 | 跑赢大盘 → 中性 |
04/28/2021 | — | 古根海姆 | 降级 | 买入 → 中性 | |
03/16/2021 | 1280.53% | 贝尔德 | 23 美元 → 39 美元 | 升级 | 中性 → 跑赢大盘 |
2020 年 10 月 15 日 | — | 贝尔德 | 降级 | 跑赢大盘 → 中性 | |
2020 年 8 月 19 日 | 1032.74% | 花旗集团 | 15 美元 → 32 美元 | 升级 | 中性 → 买入 |
07/07/2020 | 643.36% | 贝尔德 | 28 美元 → 21 美元 | 维护 | 跑赢大盘 |
03/06/2020 | 289.38% | 高盛 | 15 美元 → 11 美元 | 降级 | 中性 → 卖出 |
2020 年 2 月 19 日 | 1280.53% | BTIG | 37 美元 → 39 美元 | 维护 | 买 |
08/09/2019 | — | BTIG | 启动覆盖范围开启 | → 购买 | |
05/24/2019 | — | 花旗集团 | 假设 | → 中立 | |
03/14/2019 | — | 威廉布莱尔 | 启动覆盖范围开启 | → 跑赢大盘 | |
12/19/2018 | 784.96% | 高盛 | → 25 美元 | 启动覆盖范围开启 | → 中立 |
What is the target price for Cellectis (CLLS)?
Cellectis(CLLS)的目标价格是多少?
The latest price target for Cellectis (NASDAQ: CLLS) was reported by JMP Securities on November 1, 2023. The analyst firm set a price target for $6.00 expecting CLLS to rise to within 12 months (a possible 112.39% upside). 7 analyst firms have reported ratings in the last year.
JMP Securities于2023年11月1日公布了Cellectis(纳斯达克股票代码:CLLS)的最新目标股价。该分析公司将目标股价定为6.00美元,预计CLLS将在12个月内升至12个月内(可能上涨112.39%)。去年有7家分析公司公布了评级。
What is the most recent analyst rating for Cellectis (CLLS)?
分析师对Cellectis(CLLS)的最新评级是多少?
The latest analyst rating for Cellectis (NASDAQ: CLLS) was provided by JMP Securities, and Cellectis reiterated their market outperform rating.
JMP Securities(纳斯达克股票代码:CLLS)的最新分析师评级由JMP Securities提供,Cellectis重申了其市场跑赢大盘的评级。
When is the next analyst rating going to be posted or updated for Cellectis (CLLS)?
Cellectis(CLLS)的下一次分析师评级何时发布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cellectis, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cellectis was filed on November 1, 2023 so you should expect the next rating to be made available sometime around November 1, 2024.
分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与Cellectis的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月做一次这样的评级,因此每家公司每年应该获得4次评级。Cellectis的最新评级是在2023年11月1日发布的,因此您应该预计下一个评级将在2024年11月1日左右公布。
Is the Analyst Rating Cellectis (CLLS) correct?
分析师对Cellectis(CLLS)的评级是否正确?
While ratings are subjective and will change, the latest Cellectis (CLLS) rating was a reiterated with a price target of $6.00 to $6.00. The current price Cellectis (CLLS) is trading at is $2.83, which is out of the analyst's predicted range.
尽管评级是主观的,并且会发生变化,但最新的Cellectis(CLLS)评级得到了重申,目标股价为6.00美元至6.00美元。Cellectis(CLLS)目前的交易价格为2.83美元,超出了分析师的预期区间。